
-
England captain Stokes relishing Pant battle in India series
-
Ukraine hits Russian city deep behind front line, leaves three dead
-
Hinault backs 'complete rider' Pogacar for Tour de France glory
-
Third seed Pegula suffers shock Wimbledon exit
-
Stocks struggle tracking US trade deal prospects
-
Djokovic launches Grand Slam history bid at Wimbledon
-
UK arrests three in Lucy Letby hospital probe
-
Europe on high alert as surprise early heatwave creeps north
-
UK govt faces major rebellion in welfare vote
-
Indian capital bans fuel for old cars in anti-pollution bid
-
Flintoff rules himself out of top England coaching job
-
Russia ramps up drone strikes on Ukraine in June: AFP analysis
-
Japan had hottest June on record: weather agency
-
Asian stocks rise on trade deal hopes, Tokyo hit by Trump warning
-
Thailand's PM suspended by Constitutional Court
-
Blur will return to musical oasis, says drummer Rowntree
-
CBEX crypto scam: AI-hyped Ponzi scheme defrauds African investors
-
Inzaghi hails 'extraordinary' Al Hilal after City upset
-
Man City, Inter Milan crash out of Club World Cup in last 16
-
North Korea's Kim shown honouring troops killed in Russia-Ukraine war
-
Saudi's Al Hilal knock Man City out of Club World Cup in huge shock
-
'In our blood': Egyptian women reclaim belly dance from stigma
-
Online memorial for children dead in Hiroshima, Nagasaki
-
US Senate in final push to pass Trump spending bill
-
Asian stocks rise on trade deal hopes, Tokyo hit by tariff warning
-
Hong Kong rights record under fire as it marks China handover anniversary
-
Bangladeshis cling to protest dreams a year after revolution
-
Djokovic, Sinner enter Wimbledon fray
-
European security tops Denmark's EU presidency priorities
-
France expecting peak temperatures as heatwave hits Europe
-
Germany eye return to women's football summit at Euro 2025
-
'Every day I see land disappear': Suriname's battle to keep sea at bay
-
England feel pressure to perform at Euros as stars pull out
-
Clashes in Istanbul over alleged 'Prophet Mohammed' cartoon
-
India face 'last-minute' Bumrah call as they bid to level England series
-
Dortmund up against 'superstar' Ramos, aggressive Monterrey: Kovac
-
US judge orders Argentina to sell 51% stake in oil firm YPF
-
AsiaFIN's e-Invoicing Solution Surpasses 100 Customers
-
GameSquare Accelerates Crypto Strategy with Dialectic Yielding Partnership and Advisory Appointments
-
Old Second Completes Merger with Bancorp Financial
-
United States Antimony Corporation to Dual List on NYSE Texas Exchange
-
Envirotech Begins Delivery of Bumble Bee Electric School Bus Units with First Three Texas Orders
-
Capstone Signs LOI to Acquire Southeast Stone Co.
-
Terra Innovatum and TechSource Form Strategic Alliance to Accelerate U.S. Commercialization of SOLO(TM) Micro-Modular Reactors, Identify Strategic Funding Opportunities and Expand Access to Federal DOE and DOD Programs
-
Interactive Strength Inc. (Nasdaq: TRNR) Completes Acquisition of Wattbike, Creating a Diversified Global Fitness Platform on Track for More than $75 Million in Pro Forma 2025 Revenue
-
C2 Blockchain Inc. Expands Digital Asset Treasury with Addition of DOG Coin, the Leading Bitcoin-Native Meme Asset, Following Kraken Listing
-
EON Resources Inc. Reports Management and Directors Buy 301,000 Shares of EON Class A Common Stock
-
Let Freedom Reign!
-
Dateline Resources Reveals Significant Colosseum Gold-REE Survey Insights
-
ARIA Cybersecurity Secures Another Multiyear Contract to Protect South African Cell Tower Installations

Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
S.F.Warren--AMWN